Deliver Your News to the World

GlaxoSmithKline appoints Lon Cardon to focus Genetics on new disease targets


GlaxoSmithKline has appointed Lon Cardon to head its Genetics organisation. Lon will combine Pharmacogenetics and Medical Genetics as a single, integrated function. The primary focus of the new organisation will be to focus on the prediction of individual variations in drug response as well as to support new disease target identification and validation.

Patrick Vallance, Senior Vice President, Drug Discovery commented, “Human disease genetics has made several major breakthroughs in the last 2-3 years. Large consortia have identified genetic variants with robust and reproducible disease modifying effects. The challenge now is to integrate these advances into drug discovery and development and to determine whether common genetic variants can meaningfully impact how we should use medicines to optimise benefit and reduce risk. We have recruited a leading scientist from the gene-disease arena to apply his experience and insights to the next major genetic challenge – pharmacogenetics”.

Lon joins GSK from the Fred Hutchison Cancer Research Center, where he was Co-director of the Herbold Computational Biology Program and from the Universityof Washington, where he was Professor of Biostatistics. Prior to these appointments, Lon was Professor of Bioinformatics and a Wellcome Trust Principal Fellow at the Universityof Oxford, where he was responsible for gene-discovery activities in a number of multinational studies of common human diseases, such as the Wellcome Trust Case Control Consortium and the NIHCoordinatingCenterfor the Genes and Environment Initiative. Earlier in his career Lon was Senior Director of Bioinformatics & Statistical Genetics at Axys Pharmaceuticals and Director of Statistical Genetics at Sequana Therapeutics.
This press release is intented for business journalists and analysts/investor. Please note that this release may not have been issued in every market in which GSK operates.
© 2001-2006 GlaxoSmithKline - All rights reserved


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.